Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer.
Yunjie YangZheng LiuQifeng WangKun ChangJunyu ZhangDingwei YeYunyi KongBo DaiPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
Baseline CTC+CD133+ was a poor independent prognostic factor for metastatic castration-sensitive prostate cancer patients to progress to castration-resistant prostate cancer after receiving androgen deprivation therapy.